^
Association details:
| Biomarker: | RET mutation |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | zeteletinib (BOS-172738) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
Excerpt:
...documented local diagnosis of either 1) advanced RET gene fusion non-small cell lung cancer (NSCLC); 2) advanced RET gene mutant medullary thyroid cancer (MTC); or 3) other RET gene altered advanced tumors or NSCLC/MTC with prior specific RET gene targeted therapy...
Trial ID:
Source:
Title:
BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.
Published date:
05/19/2021
Excerpt:
…67 patients with RET-altered advanced solid tumors received once-daily oral doses of BOS172738 (10-150 mg)….BOS172738 demonstrated broad anti-tumor activity with an investigator-assessed ORR of 33% (n=18/54), a NSCLC ORR of 33% (n=10/30), MTC ORR of 44% (n=7/16, including 1 complete response)...
DOI:
10.1200/JCO.2021.39.15_suppl.3008
Trial ID:
